Davenport & Co’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Davenport & Co’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-17,538	Closed	-$823K	–	618
2015 Q3	$823K	Sell	17,538 -36,976	-68%	-$2.23M	0.01%	301
2015 Q2	$3.4M	Buy	54,514 +36,826	+208%	+$2.29M	0.05%	172
2015 Q1	$1.09M	Sell	17,688 -4,012	-18%	-$238K	0.02%	284
2014 Q4	$1.17M	Sell	21,700 -408	-2%	-$22.3K	0.02%	268
2014 Q3	$1.17M	Sell	22,108 -252	-1%	-$12.8K	0.02%	256
2014 Q2	$1.16M	Sell	22,360 -23,146	-51%	-$1.12M	0.02%	257
2014 Q1	$2.13M	Buy	45,506 +17,672	+63%	+$835K	0.04%	198
2013 Q4	$1.22M	Hold	27,834	–	–	0.02%	241
2013 Q3	$1.07M	Buy	27,834 +1,474	+6%	+$55.7K	0.02%	243
2013 Q2	$929K	Buy	+26,360	New	+$890K	0.02%	232

Other funds holding XPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

KHLMVGHM

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $1.53B AUM 20.88% 1-Year Est. Return

Davenport & Co's XPH Position: Q4 2015 in Review

Davenport & Co sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2015, closing a stake of 17,538 shares — an estimated $823K sold.

Davenport & Co first reported a position in XPH in Q2 2013 and held it in 10 quarters. The position peaked at $3.4M in Q2 2015. 76 funds tracked by Wall St. Rank hold XPH as of Q4 2015.

Davenport & Co reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2015 after selling out during the quarter.
Davenport & Co sold 17,538 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2015, an estimated $823K.
Davenport & Co first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and held it in 10 quarters.
Davenport & Co's State Street SPDR S&P Pharmaceuticals ETF position peaked at $3.4M in Q2 2015.
76 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2015.

Based on Davenport & Co's 13F filing for Q4 2015, filed 20 Jan 2016.